Designing a personalized COPD gene expression panel
We would be happy to share our in-depth white paper detailing the construction of the RT-PCR gene expression panel and its role in identifying patient-specific disease signatures during COPD acute exacerbations.
We participated in the FEBS Congress 2025 in Milan.
At this event, we presented our latest study on personalized treatment selection for patients undergoing acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
This research introduces a novel approach to uncovering patient-specific gene expression signatures, offering insights that support more targeted and effective therapeutic strategies during acute episodes.
This work is part of the COPreDict project
The COPreDict project is an advanced initiative focused on transforming the clinical management of COPD through systems-level, personalized medicine. By integrating transcriptomic profiles with clinical data, the project aims to identify molecular signatures unique to each patient during acute exacerbations.
One of its key outcomes is the development of an RT-PCR-based gene expression panel, enabling individualized diagnosis and treatment planning.
This approach has the potential to significantly enhance clinical outcomes by aligning interventions with each patient’s distinct molecular profile.
Here is the beginning of the white paper:
Designing a personalized COPD gene expression panel
Chronic Obstructive Pulmonary Disease (COPD) is a progressive, heterogeneous respiratory disease often managed with a one-size-fits-all treatment approach. T
his ignores significant molecular differences between patients, especially during acute exacerbations of COPD (AECOPD).
Blood-based gene expression profiles can reveal patient-specific disease signatures, providing a path toward precision medicine in COPD.
To enable personalized therapy selection, we developed a COPreDict system that combines a custom RT-PCR gene expression panel with a Clinical Decision Support System (CDSS). The CDSS analyzes the patient’s molecular profile and ranks therapies based on the patient-specific disease mechanism.
This white paper details the bioinformatics workflow used to construct the 93-gene PCR panel and integrate it into a CDSS for personalized COPD treatment selection, highlighting geneXplain’s proprietary tools TRANSFAC, Genome Enhancer, TRANSPATH, HumanPSD, and the geneXplain platform – at each step.
To get the full white paper leave your email….